Interleukin‐12/23 and Interleukin‐23 Inhibitors for the Treatment of Cutaneous Crohn's Disease: A Case Series From a Multi‐Institutional Registry

ABSTRACT Background Cutaneous Crohn's disease (CCD) is a granulomatous condition of the skin discontiguous from the gastrointestinal tract. Cutaneous disease rarely correlates with intestinal disease and often requires separate treatment. While the use of interleukin‐12/23 (IL‐12/IL‐23) and int...

Full description

Bibliographic Details

Published in:	JEADV Clinical Practice
Main Authors:	G. E. McKay, A. Coromilas, L. Liu, K. S. Shaw, M. Murphy, N. Punyamurthy, K. M. Santiago Soltero, W. Damsky, K. A. Wanat, A. P. Charrow, M. Rosenbach, A. Caplan, C. E. LaSenna, L. Arkin, B. E. Shields
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Subjects:	interleukin‐12/23 inhibitors interleukin‐23 inhibitors metastatic Crohn's disease risankizumab ustekinumab vedolizumab
Online Access:	https://doi.org/10.1002/jvc2.615